PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Zanzalintinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PRO-XL
- 13 Dec 2024 Status changed from not yet recruiting to recruiting.
- 26 Aug 2024 New trial record